Rifapentine
产品说明书
 |
同义名 : | DL 473;Cyclopentylrifampicin;R 773;MDL473 |
| CAS号 : | 61379-65-5 | |
| 货号 : | A444634 | |
| 分子式 : | C47H64N4O12 | |
| 纯度 : | 98% HPLC | |
| 分子量 : | 877.031 | |
| MDL号 : | MFCD00866806 | |
| 存储条件： |
Pure form Sealed in dry,Store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(57.01 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Rifapentine is an antibiotic compound used in the treatment of tuberculosis. Antibacterial Rifapentine inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme[3]. The 3-month isoniazid-rifapentine regimen is as safe and effective as other recommended latent tuberculosis infection regimens and achieves significantly higher treatment completion rates[4]. Indeed, rifapentine too may decrease blood levels of many oral antidiabetics and compete with them for protein-binding sites and/or transporters. Rifapentine seems to be more suitable for use in diabetes patients with renal impairment, owing to the fact that it does not cause renal toxicity, and it is eliminated via kidneys in smaller proportions than rifampicin[5]. Rifapentine can be administered twice weekly during the intensive phase of tuberculosis treatment and then once weekly during the continuation phase of treatment. Rifapentine is well tolerated, with most patients experiencing adverse effects at a similar rate as rifampin[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02099240 | Osteomyelitis | Early Phase 1 | Recruiting | September 2019 | United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD 收起 << |
| NCT03474198 | Tuberculosis, Pulmonary | Phase 2 Phase 3 | Recruiting | March 12, 2022 | Philippines ... 展开 >> De La Salle Health Sciences Institute Not yet recruiting Manila, Philippines Lung Center Philippines Recruiting Manila, Philippines Philippines Tuberculosis Society Incorporated (PTSI) Not yet recruiting Manila, Philippines Tropical Disease Foundation Not yet recruiting Manila, Philippines Singapore National University Hospital Not yet recruiting Singapore, Singapore Thailand King Chulalongkorn Memorial Hospital Not yet recruiting Bangkok, Thailand 收起 << |
| NCT02689089 | Tuberculosis | Phase 4 | Recruiting | September 2019 | Canada, Ontario ... 展开 >> The Ottawa Hospital - General Campus Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Gonzalo Alvarez, MD 613-737-8899 galvarez@ottawahospital.on.ca Principal Investigator: Gonzalo Alvarez, MD, FRCPC 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.14mL 0.23mL 0.11mL |
5.70mL 1.14mL 0.57mL |
11.40mL 2.28mL 1.14mL |
| 参考文献 |
|---|
|
[2]Jarvis B, Lamb HM. Rifapentine. Drugs. 1998 Oct;56(4):607-16; discussion 617. |